Note: Number refers to the running list of CPT projects 64. Physiologically-based pharmacokinetic (PBPK) modeling of
IgG (Balthasar)
65. Determinants of mAb brain distribution in mouse models
of Alzheimer’s Disease: Investigation of FcRn binding and charge (Balthasar)
66. Evaluation of mAb Brain Disposition in Alzheimer’s
Disease (Morris)
67. Investigation of the effects of co-administered drugs on
mAb pharmacokinetics (Balthasar)
68. Inclusion of “Tissue Target Dynamics” in Minimal PBPK
Models for mAb PK/PD Assessment (Jusko)
69. Quantitative Structure-Absorption Relationships (QSAR)
of mAbs (Mager)
70. Understanding and Characterizing the Bystander Effect
for Antibody-Drug Conjugates (Shah)
71. Suppression of Free TNF-α with Infliximab in Plasma and
Joints in CIA Rats (Jusko)
72. Development of Translational Physiologically-Based
Pharmacokinetic (PBPK) Model for Antibody-Drug
Conjugates (ADCs) (Shah)
73. Evaluation of the role of renal clearance and metabolism
in the altered pharmacokinetics of IgG in diabetes mellitus (Morris)
74. Very-high-resolution LC/MS for rapid, selective,
sensitive and extensive characterization and quantification of antibody-drug
conjugate to support PK studies (Qu) – partial support
75. Elimination Mechanism for Antibody-Drug Conjugates
(ADCs) with Higher DAR (Shah) – partial support
|